Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hepatitis C | 48 | 2023 | 1595 | 4.510 |
Why?
|
Hepacivirus | 46 | 2023 | 1342 | 4.010 |
Why?
|
Hepatitis B | 10 | 2024 | 709 | 1.590 |
Why?
|
Hepatitis C, Chronic | 19 | 2023 | 1032 | 1.590 |
Why?
|
Antiviral Agents | 33 | 2024 | 3068 | 1.470 |
Why?
|
CD8-Positive T-Lymphocytes | 24 | 2022 | 4652 | 0.960 |
Why?
|
Substance Abuse, Intravenous | 10 | 2023 | 528 | 0.900 |
Why?
|
Hepatitis B, Chronic | 6 | 2024 | 413 | 0.850 |
Why?
|
Interleukins | 3 | 2017 | 794 | 0.770 |
Why?
|
HIV Infections | 23 | 2024 | 17534 | 0.710 |
Why?
|
Protease Inhibitors | 4 | 2015 | 750 | 0.700 |
Why?
|
Drug Users | 3 | 2023 | 133 | 0.680 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 249 | 0.640 |
Why?
|
Ribavirin | 8 | 2021 | 396 | 0.600 |
Why?
|
Hepatitis B virus | 8 | 2024 | 531 | 0.570 |
Why?
|
Interferons | 8 | 2020 | 714 | 0.570 |
Why?
|
RNA, Viral | 12 | 2013 | 2867 | 0.550 |
Why?
|
Hepatitis, Viral, Human | 1 | 2017 | 141 | 0.550 |
Why?
|
Drug Resistance, Viral | 4 | 2010 | 868 | 0.550 |
Why?
|
Specialization | 1 | 2020 | 779 | 0.500 |
Why?
|
HLA-B Antigens | 3 | 2011 | 330 | 0.480 |
Why?
|
Major Histocompatibility Complex | 1 | 2017 | 880 | 0.470 |
Why?
|
Prisoners | 4 | 2013 | 315 | 0.460 |
Why?
|
Communicable Disease Control | 2 | 2020 | 857 | 0.450 |
Why?
|
Needle Sharing | 1 | 2013 | 22 | 0.450 |
Why?
|
Interferon-alpha | 5 | 2019 | 910 | 0.440 |
Why?
|
Epitopes, T-Lymphocyte | 16 | 2013 | 827 | 0.440 |
Why?
|
Viral Nonstructural Proteins | 7 | 2013 | 228 | 0.400 |
Why?
|
CD4-Positive T-Lymphocytes | 9 | 2022 | 4410 | 0.370 |
Why?
|
Oligopeptides | 3 | 2015 | 1195 | 0.360 |
Why?
|
Viremia | 6 | 2012 | 727 | 0.340 |
Why?
|
HIV-1 | 7 | 2013 | 6948 | 0.340 |
Why?
|
Mass Screening | 4 | 2021 | 5451 | 0.330 |
Why?
|
HLA-B27 Antigen | 3 | 2013 | 66 | 0.290 |
Why?
|
Polyethylene Glycols | 3 | 2009 | 1189 | 0.290 |
Why?
|
Viral Load | 8 | 2020 | 3385 | 0.280 |
Why?
|
Virus Replication | 6 | 2013 | 2457 | 0.270 |
Why?
|
Hepatitis C Antibodies | 5 | 2013 | 151 | 0.260 |
Why?
|
Immunologic Memory | 2 | 2021 | 1377 | 0.230 |
Why?
|
Humans | 98 | 2024 | 766432 | 0.230 |
Why?
|
Practice Guidelines as Topic | 1 | 2021 | 7426 | 0.220 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2007 | 663 | 0.220 |
Why?
|
Rheumatic Diseases | 2 | 2021 | 656 | 0.220 |
Why?
|
Physicians | 1 | 2020 | 4591 | 0.200 |
Why?
|
Antigens, Viral | 2 | 2021 | 995 | 0.190 |
Why?
|
Epitopes | 3 | 2021 | 2526 | 0.180 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2022 | 174 | 0.170 |
Why?
|
Cohort Studies | 16 | 2022 | 41703 | 0.170 |
Why?
|
Male | 49 | 2021 | 363975 | 0.170 |
Why?
|
Genotype | 9 | 2017 | 13034 | 0.170 |
Why?
|
Immunodominant Epitopes | 3 | 2011 | 244 | 0.170 |
Why?
|
Liver Diseases | 3 | 2020 | 1303 | 0.160 |
Why?
|
Hepatitis D | 1 | 2019 | 23 | 0.160 |
Why?
|
Kidney Failure, Chronic | 2 | 2023 | 2505 | 0.160 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 227 | 0.160 |
Why?
|
Aspartate Aminotransferases | 1 | 2020 | 416 | 0.160 |
Why?
|
Acute Disease | 9 | 2017 | 7240 | 0.160 |
Why?
|
Jaundice | 1 | 2019 | 95 | 0.150 |
Why?
|
Adenosine Monophosphate | 1 | 2020 | 232 | 0.150 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3109 | 0.150 |
Why?
|
Latent Tuberculosis | 1 | 2021 | 223 | 0.150 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3231 | 0.150 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2019 | 1362 | 0.150 |
Why?
|
Female | 43 | 2021 | 396354 | 0.140 |
Why?
|
Liver | 5 | 2020 | 7570 | 0.140 |
Why?
|
Alanine | 1 | 2020 | 613 | 0.140 |
Why?
|
Infectious Disease Medicine | 1 | 2017 | 50 | 0.140 |
Why?
|
Adult | 31 | 2022 | 223253 | 0.140 |
Why?
|
Middle Aged | 35 | 2022 | 223127 | 0.140 |
Why?
|
Ritonavir | 3 | 2023 | 331 | 0.130 |
Why?
|
Substance-Related Disorders | 1 | 2013 | 4418 | 0.130 |
Why?
|
Immunity, Innate | 4 | 2020 | 3078 | 0.130 |
Why?
|
Hydroxychloroquine | 1 | 2020 | 427 | 0.130 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2004 | 2205 | 0.130 |
Why?
|
Genetic Predisposition to Disease | 1 | 2017 | 18075 | 0.130 |
Why?
|
Receptors, Fc | 1 | 2019 | 537 | 0.120 |
Why?
|
Fatigue | 1 | 2022 | 1554 | 0.120 |
Why?
|
Cryoglobulinemia | 1 | 2015 | 84 | 0.120 |
Why?
|
Uridine Monophosphate | 1 | 2015 | 67 | 0.120 |
Why?
|
Piperidines | 2 | 2021 | 1662 | 0.120 |
Why?
|
HLA-A Antigens | 3 | 2010 | 223 | 0.120 |
Why?
|
Fluorenes | 1 | 2015 | 160 | 0.110 |
Why?
|
North America | 1 | 2017 | 1287 | 0.110 |
Why?
|
Comorbidity | 5 | 2020 | 10579 | 0.110 |
Why?
|
DNA, Viral | 4 | 2024 | 2200 | 0.110 |
Why?
|
Interferon Type I | 1 | 2017 | 568 | 0.110 |
Why?
|
Professional Role | 1 | 2016 | 314 | 0.110 |
Why?
|
HIV | 2 | 2019 | 1588 | 0.110 |
Why?
|
Antigen Presentation | 2 | 2010 | 1251 | 0.100 |
Why?
|
Hepatitis B e Antigens | 2 | 2024 | 135 | 0.100 |
Why?
|
Disease Progression | 6 | 2020 | 13632 | 0.100 |
Why?
|
Genes, MHC Class I | 2 | 2010 | 236 | 0.100 |
Why?
|
Polysaccharides | 1 | 2019 | 1020 | 0.100 |
Why?
|
Homosexuality, Male | 2 | 2012 | 1342 | 0.100 |
Why?
|
Phylogeny | 6 | 2009 | 2839 | 0.100 |
Why?
|
Vaccination | 2 | 2021 | 3434 | 0.100 |
Why?
|
Endocarditis | 1 | 2016 | 348 | 0.100 |
Why?
|
Mutation, Missense | 2 | 2011 | 2590 | 0.090 |
Why?
|
Pyrimidines | 2 | 2021 | 3047 | 0.090 |
Why?
|
Seroepidemiologic Studies | 1 | 2013 | 404 | 0.090 |
Why?
|
Proline | 3 | 2021 | 454 | 0.090 |
Why?
|
Suppression, Genetic | 1 | 2011 | 190 | 0.090 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2024 | 2329 | 0.090 |
Why?
|
Antigens, Surface | 2 | 2022 | 1617 | 0.090 |
Why?
|
Young Adult | 11 | 2020 | 59928 | 0.090 |
Why?
|
Europe | 1 | 2017 | 3427 | 0.090 |
Why?
|
2-Naphthylamine | 2 | 2021 | 20 | 0.090 |
Why?
|
Prisons | 2 | 2010 | 178 | 0.090 |
Why?
|
HLA Antigens | 3 | 2011 | 1339 | 0.090 |
Why?
|
Benzimidazoles | 1 | 2015 | 861 | 0.090 |
Why?
|
Placenta | 1 | 2019 | 1725 | 0.080 |
Why?
|
Syphilis | 1 | 2012 | 243 | 0.080 |
Why?
|
Cause of Death | 1 | 2020 | 3714 | 0.080 |
Why?
|
Immunity, Active | 1 | 2009 | 58 | 0.080 |
Why?
|
Killer Cells, Natural | 2 | 2019 | 2210 | 0.080 |
Why?
|
Creatinine | 1 | 2015 | 1916 | 0.080 |
Why?
|
Psychoses, Substance-Induced | 1 | 2010 | 98 | 0.080 |
Why?
|
Macrocyclic Compounds | 3 | 2019 | 68 | 0.080 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2023 | 2306 | 0.080 |
Why?
|
Uracil | 2 | 2021 | 210 | 0.080 |
Why?
|
Cyclopropanes | 2 | 2021 | 436 | 0.080 |
Why?
|
Viral Proteins | 4 | 2010 | 1801 | 0.080 |
Why?
|
Remission, Spontaneous | 4 | 2013 | 384 | 0.080 |
Why?
|
Pharmacogenetics | 1 | 2012 | 682 | 0.080 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2009 | 113 | 0.080 |
Why?
|
Lactams, Macrocyclic | 2 | 2021 | 319 | 0.080 |
Why?
|
Liver Neoplasms | 1 | 2024 | 4356 | 0.070 |
Why?
|
Acute Kidney Injury | 1 | 2020 | 1943 | 0.070 |
Why?
|
Survival Analysis | 2 | 2013 | 10092 | 0.070 |
Why?
|
Immunoassay | 2 | 2012 | 742 | 0.070 |
Why?
|
Immunoglobulin G | 1 | 2019 | 4559 | 0.070 |
Why?
|
T-Lymphocytes | 4 | 2009 | 10263 | 0.070 |
Why?
|
Aged | 19 | 2020 | 171234 | 0.070 |
Why?
|
Tissue Donors | 1 | 2017 | 2390 | 0.070 |
Why?
|
Mutation | 7 | 2011 | 30220 | 0.070 |
Why?
|
Pilot Projects | 4 | 2015 | 8720 | 0.070 |
Why?
|
HLA-A3 Antigen | 1 | 2006 | 34 | 0.070 |
Why?
|
HIV Core Protein p24 | 1 | 2006 | 245 | 0.070 |
Why?
|
Lymphocyte Activation | 6 | 2019 | 5502 | 0.070 |
Why?
|
Genes, T-Cell Receptor beta | 1 | 2006 | 70 | 0.070 |
Why?
|
Cross Infection | 1 | 2015 | 1427 | 0.070 |
Why?
|
Glomerular Filtration Rate | 1 | 2015 | 2230 | 0.070 |
Why?
|
Epitope Mapping | 1 | 2007 | 300 | 0.070 |
Why?
|
Recombinant Proteins | 4 | 2009 | 6507 | 0.060 |
Why?
|
Tryptophan Synthase | 2 | 1995 | 9 | 0.060 |
Why?
|
Cross-Sectional Studies | 4 | 2023 | 26294 | 0.060 |
Why?
|
Meningitis, Bacterial | 1 | 2007 | 222 | 0.060 |
Why?
|
Liver Function Tests | 2 | 2020 | 527 | 0.060 |
Why?
|
HLA-B8 Antigen | 1 | 2004 | 16 | 0.060 |
Why?
|
Lectins, C-Type | 1 | 2008 | 592 | 0.060 |
Why?
|
Lymphocyte Count | 1 | 2006 | 794 | 0.060 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2011 | 1802 | 0.060 |
Why?
|
Program Evaluation | 1 | 2013 | 2503 | 0.060 |
Why?
|
United States | 6 | 2021 | 72910 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2015 | 2101 | 0.060 |
Why?
|
Psychiatry | 1 | 2016 | 1714 | 0.060 |
Why?
|
Lymphoma, AIDS-Related | 1 | 2004 | 79 | 0.060 |
Why?
|
Treatment Outcome | 9 | 2017 | 65202 | 0.050 |
Why?
|
Interferon-gamma | 3 | 2007 | 3159 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2017 | 7607 | 0.050 |
Why?
|
Hydroxylamines | 1 | 2023 | 39 | 0.050 |
Why?
|
Disease Transmission, Infectious | 1 | 2009 | 560 | 0.050 |
Why?
|
Alanine Transaminase | 2 | 2020 | 608 | 0.050 |
Why?
|
Shame | 1 | 2023 | 80 | 0.050 |
Why?
|
Temporal Bone | 1 | 2007 | 683 | 0.050 |
Why?
|
Odds Ratio | 1 | 2015 | 9654 | 0.050 |
Why?
|
Logistic Models | 2 | 2015 | 13276 | 0.050 |
Why?
|
Histocompatibility Testing | 1 | 2004 | 726 | 0.050 |
Why?
|
Risk Factors | 6 | 2020 | 74828 | 0.050 |
Why?
|
Hepatitis B Surface Antigens | 1 | 2024 | 293 | 0.050 |
Why?
|
Immunity, Cellular | 2 | 2007 | 1560 | 0.050 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2007 | 1150 | 0.050 |
Why?
|
Genome-Wide Association Study | 3 | 2017 | 12807 | 0.050 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2017 | 16042 | 0.050 |
Why?
|
CD4 Lymphocyte Count | 2 | 2007 | 2585 | 0.050 |
Why?
|
Canada | 2 | 2021 | 2123 | 0.050 |
Why?
|
Lung | 1 | 2020 | 10064 | 0.050 |
Why?
|
Antigens, CD | 2 | 2013 | 4031 | 0.050 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily B | 2 | 2014 | 85 | 0.050 |
Why?
|
Self Report | 1 | 2013 | 3770 | 0.050 |
Why?
|
Cerebrospinal Fluid | 1 | 2004 | 540 | 0.050 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2009 | 1899 | 0.050 |
Why?
|
Drug Therapy, Combination | 3 | 2019 | 6306 | 0.050 |
Why?
|
High Mobility Group Proteins | 1 | 2021 | 179 | 0.040 |
Why?
|
Liver Transplantation | 1 | 2013 | 2417 | 0.040 |
Why?
|
Massachusetts | 3 | 2020 | 8885 | 0.040 |
Why?
|
Sulfonamides | 2 | 2021 | 1978 | 0.040 |
Why?
|
Intubation | 1 | 2020 | 140 | 0.040 |
Why?
|
Surface-Active Agents | 1 | 2020 | 150 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 124 | 0.040 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2005 | 975 | 0.040 |
Why?
|
Recurrence | 2 | 2016 | 8478 | 0.040 |
Why?
|
Valine | 1 | 2021 | 410 | 0.040 |
Why?
|
Risk Assessment | 4 | 2022 | 24272 | 0.040 |
Why?
|
Belgium | 1 | 2019 | 119 | 0.040 |
Why?
|
Follow-Up Studies | 4 | 2015 | 39283 | 0.040 |
Why?
|
Liver Cirrhosis | 2 | 2024 | 1960 | 0.040 |
Why?
|
Phenotype | 4 | 2021 | 16721 | 0.040 |
Why?
|
Aspartic Acid Endopeptidases | 1 | 2020 | 308 | 0.040 |
Why?
|
Glycerophosphates | 2 | 1995 | 51 | 0.040 |
Why?
|
Polymerase Chain Reaction | 2 | 2007 | 6061 | 0.040 |
Why?
|
Herpesvirus 4, Human | 1 | 2004 | 1079 | 0.040 |
Why?
|
Cell Degranulation | 1 | 2019 | 276 | 0.040 |
Why?
|
Cytokines | 2 | 2022 | 7436 | 0.040 |
Why?
|
Anilides | 1 | 2021 | 413 | 0.040 |
Why?
|
Heroin Dependence | 1 | 2019 | 174 | 0.040 |
Why?
|
Amino Acid Sequence | 5 | 2009 | 13410 | 0.040 |
Why?
|
Carbamates | 2 | 2010 | 191 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1377 | 0.040 |
Why?
|
Wounds and Injuries | 1 | 2010 | 2513 | 0.040 |
Why?
|
Anti-Retroviral Agents | 1 | 2007 | 1786 | 0.040 |
Why?
|
Peptides | 2 | 2007 | 4344 | 0.040 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 624 | 0.040 |
Why?
|
Mucins | 1 | 2020 | 569 | 0.040 |
Why?
|
Immunomodulation | 1 | 2021 | 548 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2010 | 4924 | 0.030 |
Why?
|
Autopsy | 1 | 2020 | 1011 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 2020 | 1887 | 0.030 |
Why?
|
Mental Disorders | 1 | 2016 | 6869 | 0.030 |
Why?
|
Salmonella typhimurium | 2 | 1995 | 348 | 0.030 |
Why?
|
Brazil | 2 | 2011 | 1249 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1100 | 0.030 |
Why?
|
Pandemics | 3 | 2020 | 8729 | 0.030 |
Why?
|
Receptors, IgG | 1 | 2019 | 562 | 0.030 |
Why?
|
Review Literature as Topic | 1 | 2017 | 297 | 0.030 |
Why?
|
Health Personnel | 1 | 2009 | 3382 | 0.030 |
Why?
|
Prognosis | 3 | 2020 | 29922 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2004 | 926 | 0.030 |
Why?
|
Protein Conformation | 2 | 2010 | 3946 | 0.030 |
Why?
|
Aged, 80 and over | 3 | 2020 | 59538 | 0.030 |
Why?
|
Retrospective Studies | 5 | 2020 | 81588 | 0.030 |
Why?
|
Natural Cytotoxicity Triggering Receptor 1 | 1 | 2014 | 29 | 0.030 |
Why?
|
Immunity | 1 | 2020 | 1002 | 0.030 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2012 | 1441 | 0.030 |
Why?
|
Chemokines | 1 | 2019 | 962 | 0.030 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 1 | 2014 | 94 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2653 | 0.030 |
Why?
|
Perforin | 1 | 2014 | 167 | 0.030 |
Why?
|
Quinolines | 2 | 2010 | 769 | 0.030 |
Why?
|
Evolution, Molecular | 3 | 2007 | 1891 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 4561 | 0.030 |
Why?
|
Genome, Viral | 2 | 2007 | 674 | 0.030 |
Why?
|
Amino Acid Substitution | 2 | 2010 | 1742 | 0.030 |
Why?
|
Molecular Sequence Data | 4 | 2007 | 17605 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2020 | 10379 | 0.030 |
Why?
|
Amino Acids | 2 | 2010 | 1711 | 0.030 |
Why?
|
Biopsy | 1 | 2004 | 6778 | 0.030 |
Why?
|
Time Factors | 2 | 2017 | 40116 | 0.030 |
Why?
|
Adaptive Immunity | 1 | 2017 | 733 | 0.030 |
Why?
|
Tryptophan | 1 | 1994 | 484 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4850 | 0.020 |
Why?
|
Thiazoles | 2 | 2010 | 1528 | 0.020 |
Why?
|
Weight Loss | 1 | 2022 | 2711 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1949 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2017 | 2718 | 0.020 |
Why?
|
Point Mutation | 1 | 1995 | 1591 | 0.020 |
Why?
|
Adolescent | 4 | 2019 | 88898 | 0.020 |
Why?
|
Prevalence | 1 | 2007 | 15820 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 146 | 0.020 |
Why?
|
Sampling Studies | 1 | 2011 | 614 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2010 | 140 | 0.020 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2009 | 50 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 328 | 0.020 |
Why?
|
Cost-Benefit Analysis | 2 | 2014 | 5535 | 0.020 |
Why?
|
Blood-Borne Pathogens | 1 | 2009 | 52 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2015 | 15639 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2014 | 1866 | 0.020 |
Why?
|
Chromatin | 1 | 2021 | 2979 | 0.020 |
Why?
|
Needlestick Injuries | 1 | 2009 | 71 | 0.020 |
Why?
|
Phenylthiourea | 1 | 2008 | 10 | 0.020 |
Why?
|
Cooperative Behavior | 1 | 2016 | 1512 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 3803 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2019 | 12979 | 0.020 |
Why?
|
Australia | 1 | 2012 | 1262 | 0.020 |
Why?
|
Gene Regulatory Networks | 1 | 2017 | 1752 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2020 | 3689 | 0.020 |
Why?
|
Animals | 3 | 2009 | 168887 | 0.020 |
Why?
|
Immunologic Factors | 1 | 2017 | 1594 | 0.020 |
Why?
|
Cell Differentiation | 2 | 2021 | 11648 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2020 | 15897 | 0.020 |
Why?
|
Earache | 1 | 2007 | 14 | 0.020 |
Why?
|
Drosophila Proteins | 1 | 2017 | 1704 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2020 | 10740 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1972 | 0.020 |
Why?
|
Epigenesis, Genetic | 1 | 2021 | 3824 | 0.020 |
Why?
|
Netherlands | 1 | 2012 | 2277 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9333 | 0.020 |
Why?
|
Alleles | 2 | 2010 | 6894 | 0.020 |
Why?
|
Pneumocephalus | 1 | 2007 | 46 | 0.020 |
Why?
|
Genetic Variation | 2 | 2017 | 6612 | 0.020 |
Why?
|
Receptors, Immunologic | 1 | 2013 | 1418 | 0.020 |
Why?
|
Intensive Care Units | 1 | 2020 | 3798 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2020 | 11059 | 0.020 |
Why?
|
Incidence | 3 | 2012 | 21509 | 0.020 |
Why?
|
Binding Sites | 2 | 2011 | 6010 | 0.020 |
Why?
|
Heart | 1 | 2020 | 4421 | 0.020 |
Why?
|
Length of Stay | 1 | 2020 | 6490 | 0.020 |
Why?
|
Consensus Sequence | 1 | 2007 | 363 | 0.020 |
Why?
|
Serotyping | 1 | 2007 | 331 | 0.020 |
Why?
|
Speech Disorders | 1 | 2007 | 178 | 0.020 |
Why?
|
Gene Products, nef | 1 | 2006 | 101 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12423 | 0.020 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 149 | 0.020 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2007 | 1056 | 0.020 |
Why?
|
Disease Outbreaks | 1 | 2015 | 1761 | 0.020 |
Why?
|
Survival Rate | 1 | 2020 | 12825 | 0.020 |
Why?
|
Gene Frequency | 1 | 2013 | 3624 | 0.020 |
Why?
|
Ultrasonography | 1 | 2019 | 5988 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5782 | 0.020 |
Why?
|
5' Untranslated Regions | 1 | 2007 | 255 | 0.020 |
Why?
|
Ki-67 Antigen | 1 | 2008 | 629 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2020 | 3249 | 0.020 |
Why?
|
Unconsciousness | 1 | 2007 | 252 | 0.020 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3690 | 0.020 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2005 | 89 | 0.020 |
Why?
|
Chronic Disease | 3 | 2005 | 9352 | 0.020 |
Why?
|
Intracranial Hypertension | 1 | 2007 | 191 | 0.020 |
Why?
|
Life Expectancy | 1 | 2012 | 1249 | 0.020 |
Why?
|
Interleukin-2 | 1 | 2012 | 1894 | 0.010 |
Why?
|
Models, Molecular | 2 | 2010 | 5385 | 0.010 |
Why?
|
Nucleic Acid Amplification Techniques | 1 | 2007 | 335 | 0.010 |
Why?
|
Prospective Studies | 3 | 2016 | 54826 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2727 | 0.010 |
Why?
|
Cross Reactions | 1 | 2006 | 825 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12061 | 0.010 |
Why?
|
Cell Proliferation | 2 | 2012 | 10438 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2005 | 609 | 0.010 |
Why?
|
Risk-Taking | 1 | 2009 | 1021 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2008 | 754 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2004 | 317 | 0.010 |
Why?
|
Sequence Alignment | 1 | 2007 | 2176 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2013 | 5890 | 0.010 |
Why?
|
Fatal Outcome | 1 | 2007 | 1838 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 2007 | 2746 | 0.010 |
Why?
|
Hepatitis C Antigens | 1 | 2002 | 34 | 0.010 |
Why?
|
HIV Seropositivity | 1 | 2008 | 961 | 0.010 |
Why?
|
HLA-A2 Antigen | 1 | 2002 | 207 | 0.010 |
Why?
|
Antibodies, Neutralizing | 1 | 2012 | 2010 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8042 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2017 | 9521 | 0.010 |
Why?
|
Serine | 2 | 1995 | 829 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10860 | 0.010 |
Why?
|
Brain | 1 | 2007 | 27156 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10812 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2007 | 1851 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4474 | 0.010 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2010 | 2884 | 0.010 |
Why?
|
Predictive Value of Tests | 2 | 2007 | 15390 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2009 | 1807 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2019 | 26388 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3241 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2016 | 5509 | 0.010 |
Why?
|
Transcription Factors | 1 | 2017 | 12147 | 0.010 |
Why?
|
Kinetics | 2 | 1995 | 6285 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 30235 | 0.010 |
Why?
|
Indoles | 2 | 1995 | 1832 | 0.010 |
Why?
|
Membrane Proteins | 1 | 2013 | 7866 | 0.010 |
Why?
|
Up-Regulation | 1 | 2005 | 4141 | 0.010 |
Why?
|
Radioisotope Dilution Technique | 1 | 1995 | 70 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14643 | 0.010 |
Why?
|
Base Sequence | 1 | 2007 | 12412 | 0.010 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 4779 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 22245 | 0.010 |
Why?
|
Cell Line | 1 | 2009 | 15563 | 0.010 |
Why?
|
Genetic Testing | 1 | 2008 | 3590 | 0.010 |
Why?
|
Carbon Radioisotopes | 1 | 1995 | 544 | 0.010 |
Why?
|
Mathematics | 1 | 1995 | 696 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2012 | 7475 | 0.010 |
Why?
|
Postoperative Complications | 1 | 2016 | 15818 | 0.010 |
Why?
|
Macromolecular Substances | 1 | 1995 | 1431 | 0.010 |
Why?
|
Catalysis | 1 | 1994 | 767 | 0.010 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1995 | 1677 | 0.010 |
Why?
|
Structure-Activity Relationship | 1 | 1995 | 3053 | 0.010 |
Why?
|
Crystallography, X-Ray | 1 | 1994 | 1947 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2005 | 18979 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2002 | 5129 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2007 | 20706 | 0.000 |
Why?
|
Models, Theoretical | 1 | 1995 | 3562 | 0.000 |
Why?
|